Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Feb;8(1):31-6.
doi: 10.1007/s11892-008-0007-0.

Challenges in developing drugs for the metabolic syndrome

Affiliations
Review

Challenges in developing drugs for the metabolic syndrome

Glenn Matfin. Curr Diab Rep. 2008 Feb.

Abstract

Metabolic syndrome refers to a clustering of established and emerging cardiovascular disease (CVD) risk factors within a single individual. The established risk factors--such as obesity, diabetes, dyslipidemia, hypertension--and other emerging risk factors are closely related to central obesity (especially intra-abdominal adiposity). Insulin resistance is also an important factor in this syndrome's etiology. However, despite the potential use of having all the CVD risk factors under an umbrella diagnosis of metabolic syndrome, debate continues about the very existence of the metabolic syndrome. Despite the controversies, many existing therapies and new drugs in development are targeting the metabolic syndrome. To date, no drugs are approved specifically for treating the metabolic syndrome. This article discusses some of the challenges in developing therapies for the metabolic syndrome.

PubMed Disclaimer

Similar articles

References

    1. Postgrad Med J. 2005 Jan;81(951):1-6 - PubMed
    1. Circulation. 2003 Jan 28;107(3):363-9 - PubMed
    1. Diabetes Care. 2005 Nov;28(11):2745-9 - PubMed
    1. Trends Endocrinol Metab. 2005 Aug;16(6):254-60 - PubMed
    1. Ann Intern Med. 2000 Jul 18;133(2):154-6 - PubMed

LinkOut - more resources